Member Info for alfista

So, deliberately just below the magic 30% level, for now at least.
The puzzle, if there is one, is that one would have expected the crisis in production of the core of the business is entering unknown territory, with many producers unwilling to ask the price they would have to in order to break even. If TPT were to be buying at the new surcharge applied this week, their retail price would require eye watering upwards revision. And, as gas prices have risen sharply since the surcharge was announced, there's every reason to expect further additions.
What value would this leave in the short to medium term?

Just shy of £20k gone through at .90 on Aquis

All a bit puzzling really. The gas crisis is causing all kinds of issues for tile producers, costs are something close to 10 x what they budgeted for. That's got to cause issues of availability to retailers, not to mention eye watering price surcharges. Couple that with a recent doubling of transport costs, and I'd have thought this bloke has got his timing all wrong. Still, if you're in it for the long term, it could well do more damage to other retailers. Survival of the fittest.
IMHO

Were there any options at that price?
Certainly a credible explanation

and Bid raised.
Interesting

That explains why Bid/Ask remains unchanged.
What the heck all those other loony tunes trades are is anyone's guess

If anyone wanted to sell that many in one go they wouldn't have got that price.
If someone wanted to buy that many in one go, they also wouldn't get that price.
Conundrum innit.

And a corner shop would have a newly signed collaboration with an industry giant ?

No, you must analyse the loss. Has it increased or decreased?
Would a single multiple of current sales eliminate it?
Would several multiples of current sales make it a distant memory?

Just simple business really

So, set the price lower, less revenue, less gross margin.
Meanwhile, spend loads on promotion, more outgoings, more cash consumed, higher losses.

Never ran a business, clearly.

Alf is rather relaxed actually, being strongly in profit, and still acquiring on dips.
I happen to believe that most of the posts are revenge, wind ups, ad hominem attacks on the best researcher I've ever seen.

Point is, why?

Easily avoided, just try not telling lies, or abusing long term holders who have traded more wisely.

Last week, there was a mild amount of buying, the MM reaction was to move Ask up sharply. Now, we seem to have settled back to almost no trades either way, apart from those small value nonentities of trades, which may reflect CFD's or some other kind of financial instruments. To comment on practical aspects relating to the company, such as new studies, added or removed brands etc, seems to me a reasonable way of passing the time. Even charting indicators, if that's your bag.
On the other hand, the "all is woe" loop tape stuff isn't an appropriate viewpoint given the continual development of Fruitflow as a powerful aid to health across so many physiological functions
Attempting to suppress sentiment here for revenge purposes is vile behaviour IMHO

Agreed, it's not private, so I was publicly expressing what I, and a fair few others, think.
Facts are facts, and to say nothing has happened in distorting the truth.
Plenty has happened, and plenty more is due to happen. The start of 2023 could, given a big spend on further research already, be a game changer IMHO

Linking the specific health benefit to an established brand name would be the decision of that brand owner. For Provexis, the question is whether Fruitflow portrays the plethora of health benefits established and/or under further study ?
To add an additional marketing name wouldn't be feasible cost wise right now, but surely some creative people could arrive at an image with broader appeal once funds allow.
Only a thought process at this stage, of course.

I can see what you're saying Welly, but, if a consumer wants to take O3, which after all has a much more established profile as a health supplement, they would have to take two tabs if they also wanted to take Fruitflow. If you compare the current capsule to the Swanson capsule, I don't believe you can accurately describe it as a gobstopper. I also take plant sterols from Healthspan, and they're roughly double the size of a Fruitflow+ O3 capsule.

Another point, which hasn't been discussed for a long time, is whether Provexis have to use Fruitflow as the headline brand for a future product. I've always thought it a bit clunky. Just saying.

I've got no doubt that By Health will take the ingredient forwards in a selection of product formats, in that way the presence of multiple health claims may turn out to be beneficial. For the rest of the world, how many other health products is anyone aware of that have been studied and reported on as possessing such wide variety of established and further potential applications?
Overall, I'm glad that such academic interest is ongoing so many years after Prof. Asim's initial discovery, and Prof. Niamh's excellent EFSA and US approval papers. If a few of the much vaunted "growing number of brand owners" would step up to the plate I'd be delighted. Having added a modest amount during the downward push, it's good to see a couple of strong days.

Don't get me wrong gix, The growing list of health benefits is awesome in comparison to the single one that was the aim of the EFSA approval application all those years ago. However, to be effective, a promotion has to be focussed, so, in that respect alone, I feel that brand owners may wait rather than miss out on the complete list. Obviously, I can't fathom their thinking, surely all these studies put Fruitflow on more agendas.
Hope so.

Further study.
Always further study. WSTC seems to create a monkey puzzle of differing effects. Do these studies move us closer to mass commercialisation ?

Chunkiest trades for a while today.
Hope you're right re news